Home Monitoring in eAMD Treatment

Prior treatment

• Treatment with ocriplasmin (JETREA®) in the study eye at any time.

Other illness

• Other ocular disease in the study eye that could prevent an accurate evaluation of treatment efficacy like, diabetic macular edema, posterior uveitis, corneal opacity, vein occlusion, macular dystrophy.

Lab values

• IVT anti-VEGF or steroid implants (aflibercept, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium, triamcinolone, dexamethasone, fluocinolone) for more than 1 year before inclusion.

Other

• Evidence of macular edema due to any cause other than eAMD in either eye.

• Adults (≥ 55 years old) with exudative AMD in the study eye.
• Treatment-naïve patients or patients who have started treatment with IVT anti-VEGF (aflibercept 2 mg, aflibercept 8 mg, faricimab, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium) up to 48 weeks before inclusion.
• BCVA early treatment diabetic retinopathy study (ETDRS) letter score of 85 to 34 (approximate Snellen equivalent of 20/20 to 20/200) in the study eye with decreased vision determined to be primarily the result of eAMD.
• Willing and able to comply with clinic visits and study-related procedures.
• Provide informed consent signed by study participant or legally acceptable representative.
• Own a working smartphone or tablet compatible with the OKKO Health application.
• Be able to operate the application after training according to OKKO Health indications of use: be alert and mentally competent, has competent dexterity and has normal or corrected hearing to normal audio level.